Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine
View HTML
Toggle Summary Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
Genomic Test is the First to Be Granted Medicare Coverage for Improved Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 4, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it has received a final Medicare local coverage determination
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
2018 Revenue Grew 28% to $92 million Three Commercial Products and Biopharma Collaborations to Drive Growth in 2019 Company to Host Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 20, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that members of its management team will be participating in two upcoming investor conferences. Executives from the company will be meeting with investors at the BTIG MedTech, Life Science &
View HTML
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019 . Company management will host a conference call
View HTML
Toggle Summary Veracyte to Present at the 21st Annual Needham Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 21 st Annual Needham Growth Conference in New York City on  Tuesday, January 15, 2019  at  8:40
View HTML
Toggle Summary Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer
Alliance with the Lung Cancer Initiative at Johnson & Johnson to Accelerate Development of First Nasal Swab Test for Early Lung Cancer Detection Veracyte to Host Conference Call and Webcast on January 3, 2019 at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan.
View HTML
Toggle Summary Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 37 th  Annual J.P. Morgan Healthcare Conference on Thursday , January 10, 2019  at  11:30 a.m.
View HTML
Toggle Summary Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program
20 Medical Centers Across the U.S. Now Offering First Test to Improve Diagnosis of Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 5, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that 20 medical centers across the United States are now offering the Envisia
View HTML
Toggle Summary Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 , at 9:00 a.m.
View HTML